haloperidol has been researched along with Cognition Disorders in 126 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 9.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| "Thirty-five patients with DSM-IV-TR schizophrenia and predominant negative symptoms were randomly assigned in a 12-week double-blind study to either olanzapine (15-20 mg/day) or haloperidol (15-20 mg/day)." | 9.12 | A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. ( Abad, MT; Iskander, A; Khan, A; Lindenmayer, JP; Parker, B, 2007) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 9.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "The study demonstrated two distinct processes of action on cognition between sertindole and haloperidol and the marked beneficial effects of sertindole, particularly in parameters that are regarded as schizophrenia-related cognitive disturbances." | 9.12 | Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. ( Gallhofer, B; Jaanson, P; Krieger, S; Lis, S; Mittoux, A; Tanghøj, P, 2007) |
| "After a 48-hour washout period, 25 patients with schizophrenia were randomly assigned to double-blind treatment with quetiapine or haloperidol for 6 months and evaluated with rating scales for psychotic symptoms, mood and extrapyramidal side effects, as well as standardized neuropsychological measures sensitive to 6 cognitive domains: fine motor skill, attention span, verbal reasoning and fluency, visuospatial construction and fluency, executive skills and visuomotor tracking, and immediate recall of verbal and nonverbal materials." | 9.09 | Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. ( Labelle, A; Lit, W; Malla, A; Purdon, SE, 2001) |
| "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "These results emphasize the need for more studies regarding the efficacy of haloperidol for treatment of delirium among older medical ICU patients and demonstrate the value of assessing nonintubated patients." | 7.81 | Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. ( Araujo, KL; Murphy, TE; Pisani, MA, 2015) |
| "This case report describes a 15-year-old male patient with spastic diplegic cerebral palsy, Gross Motor Function Classification System Level III, who developed severe new cognitive and motoric impairments after the administration of haloperidol." | 7.79 | Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report. ( Gelfius, CD; Mortimer, D; Potts, MA, 2013) |
| "The purpose of this article was to report a case of chorea that developed in an elderly man being treated with gabapentin for severe anxiety." | 7.75 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Here, we treated schizophrenia rat models with a systematic injection of MK-801 (0." | 5.40 | Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. ( Fang, Y; Xu, L; Zhang, C, 2014) |
| "Treatment with haloperidol and clozapine attenuated the detrimental performance effects of these challenges, with clozapine exhibiting more robust attenuation." | 5.35 | Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. ( Martinez, V; Sarter, M, 2008) |
| "In haloperidol-induced catalepsy in rats (1." | 5.30 | Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. ( Cohen, S; Levy, R; Speiser, Z, 1998) |
| "We investigated the effects of risperidone (N=16), olanzapine (N=18) and low doses of haloperidol (N=18) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients." | 5.16 | Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. ( Ayesa-Arriola, R; Crespo-Facorro, B; Gutiérrez, A; Ortíz-García de la Foz, V; Roiz-Santiáñez, R; Tabarés-Seisdedos, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL, 2012) |
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 5.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| "Community dwelling patients with schizophrenia were randomized to treatment with haloperidol (n=47) or ziprasidone dosed either once or twice daily (n=139)." | 5.14 | Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. ( Harvey, PD; Kremer, CM; Lombardo, I; Pappadopulos, E, 2009) |
| " Hip surgery patients (n = 112) aged 70 years and older, who participated in a controlled clinical trial of haloperidol prophylaxis for delirium, were followed for an average of 30 months after discharge." | 5.13 | Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. ( de Jonghe, JF; Eikelenboom, P; Kalisvaart, KJ; Kat, MG; van der Ploeg, T; van Gool, WA; Vreeswijk, R, 2008) |
| "The purpose of this study was to compare the effects of olanzapine, clozapine, and haloperidol on neurocognitive function in schizophrenic patients who present with documented episodes of physical aggression and to determine whether change in cognitive function is related to aggression." | 5.13 | Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. ( Czobor, P; Krakowski, MI; Nolan, KA, 2008) |
| "Thirty-five patients with DSM-IV-TR schizophrenia and predominant negative symptoms were randomly assigned in a 12-week double-blind study to either olanzapine (15-20 mg/day) or haloperidol (15-20 mg/day)." | 5.12 | A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. ( Abad, MT; Iskander, A; Khan, A; Lindenmayer, JP; Parker, B, 2007) |
| "The study demonstrated two distinct processes of action on cognition between sertindole and haloperidol and the marked beneficial effects of sertindole, particularly in parameters that are regarded as schizophrenia-related cognitive disturbances." | 5.12 | Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. ( Gallhofer, B; Jaanson, P; Krieger, S; Lis, S; Mittoux, A; Tanghøj, P, 2007) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 5.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "Patients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment with olanzapine (mean modal dose= 9." | 5.11 | Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. ( Christensen, BK; Gur, RC; Hamer, RM; Keefe, RS; Lewine, RR; Lieberman, JA; Sanger, TM; Seidman, LJ; Sharma, T; Sitskoorn, MM; Tohen, M; Tollefson, GD; Yurgelun-Todd, DA, 2004) |
| "307 schizophrenia subjects in their first episode of illness were recruited to participate in a clinical trial comparing the long-term efficacy of haloperidol and risperidone." | 5.11 | Correlates of cognitive deficits in first episode schizophrenia. ( Csernansky, JG; DeLisi, LE; Heydebrand, G; Hoff, AL; Rabinowitz, J; Weiser, M, 2004) |
| "During treatment with the SGAs risperidone and ziprasidone, cerebral cortical gray of 13 patients with schizophrenia expanded 20." | 5.11 | Cerebral cortical gray expansion associated with two second-generation antipsychotics. ( Christensen, JD; Garver, DL; Holcomb, JA, 2005) |
| "Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol." | 5.11 | Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. ( Davidson, M; Eerdekens, M; Harvey, PD; Rabinowitz, J, 2005) |
| "After a 48-hour washout period, 25 patients with schizophrenia were randomly assigned to double-blind treatment with quetiapine or haloperidol for 6 months and evaluated with rating scales for psychotic symptoms, mood and extrapyramidal side effects, as well as standardized neuropsychological measures sensitive to 6 cognitive domains: fine motor skill, attention span, verbal reasoning and fluency, visuospatial construction and fluency, executive skills and visuomotor tracking, and immediate recall of verbal and nonverbal materials." | 5.09 | Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. ( Labelle, A; Lit, W; Malla, A; Purdon, SE, 2001) |
| "Neurocognition and clinical symptomatology were evaluated in 27 patients with schizophrenia during a double-blind, placebo-controlled, cross-over study involving clozapine, an atypical antipsychotic agent, and haloperidol, a conventional neuroleptic." | 5.09 | Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. ( Fleming, K; Gulasekaram, B; Jin, Y; Potkin, SG, 2001) |
| "Eighteen patients (7 men, 11 women) from one of the centres taking part in a multicentre comparative study of remoxipride and haloperidol in the treatment of acute schizophrenia were investigated separately to study the effect of the two neuroleptic drugs on cognitive abilities." | 5.06 | Cognitive disturbances in neuroleptic therapy. ( Klieser, E; Strauss, WH, 1990) |
| "There is probably little or no difference between haloperidol and placebo for preventing ICU delirium but further studies are needed to increase our confidence in the findings." | 4.98 | Interventions for preventing intensive care unit delirium in adults. ( Bekker Mortensen, C; Egerod, I; Greve, IE; Herling, SF; Møller, AM; Svenningsen, H; Thomsen, T; Vasilevskis, EE, 2018) |
| "Prospective, double-blind, randomized trials comparing atypical antipsychotic drugs (APDs) to typical APDs, such as haloperidol, indicate that atypical APDs provide a modest benefit to cognitive function in schizophrenia." | 4.84 | A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. ( Meltzer, HY; Purdon, SE; Woodward, ND; Zald, DH, 2007) |
| "Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "These results emphasize the need for more studies regarding the efficacy of haloperidol for treatment of delirium among older medical ICU patients and demonstrate the value of assessing nonintubated patients." | 3.81 | Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. ( Araujo, KL; Murphy, TE; Pisani, MA, 2015) |
| "A 60-year-old man with rapidly progressive frontotemporal dementia complicated by severe aggression was managed in specialised psychogeriatric services and high-dose haloperidol was used." | 3.80 | Managing severe aggression in frontotemporal dementia. ( Flynn, P; McKellar, D; Powell, A; Rischbieth, S, 2014) |
| "This case report describes a 15-year-old male patient with spastic diplegic cerebral palsy, Gross Motor Function Classification System Level III, who developed severe new cognitive and motoric impairments after the administration of haloperidol." | 3.79 | Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report. ( Gelfius, CD; Mortimer, D; Potts, MA, 2013) |
| "Secondary analysis of haloperidol prophylaxis for delirium clinical trial data." | 3.77 | Anesthesia and postoperative delirium in older adults undergoing hip surgery. ( de Jonghe, JF; Eikelenboom, P; Groot, E; Kalisvaart, KJ; Ploeg, TV; Schmand, B; Slor, CJ; Snoeck, M; van Gool, WA; Vreeswijk, R, 2011) |
| "The purpose of this article was to report a case of chorea that developed in an elderly man being treated with gabapentin for severe anxiety." | 3.75 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "Disruptions in 5-CSRTT performance induced by repeated PCP administration are prevented by chronic clozapine treatment and may constitute a useful animal model of some cognitive symptoms of schizophrenia." | 3.74 | Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. ( Amitai, N; Markou, A; Semenova, S, 2007) |
| "Sixty-seven outpatients with schizophrenia receiving stable doses of risperidone or haloperidol were evaluated for akathisia and other extrapyramidal side effects." | 3.74 | Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. ( Byun, HJ; Kim, JH, 2007) |
| "One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol." | 3.74 | Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. ( Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C, 2007) |
| "Gains from earning rates for employed persons with schizophrenia, savings in informal caregiver costs and other human benefits could justify an incremental cost of 19,609 US dollars for each additional employable person prescribed risperidone." | 3.72 | Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. ( Ganguly, R; Martin, BC; Miller, LS, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Risperidone treatment, however, was more effective in the reduction of negative symptoms." | 2.71 | The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. ( Cohen, H; Pourcher, E; Rémillard, S, 2005) |
| "Haloperidol-treated patients exhibited significant decreases in gray matter volume, whereas olanzapine-treated patients did not." | 2.71 | Antipsychotic drug effects on brain morphology in first-episode psychosis. ( Charles, C; Green, AI; Gu, H; Gur, RE; Hamer, RM; Kahn, RS; Keefe, RS; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, GD; Zipursky, R, 2005) |
| "Clinical trials for the treatment of schizophrenia now often include cognitive assessments in addition to clinical ratings of symptoms." | 2.71 | Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study. ( Artiola i Fortuny, L; De Smedt, G; Harvey, PD; Vester-Blockland, E, 2003) |
| "Alprazolam was as effective as low dose haloperidol in this population." | 2.69 | Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. ( Benfield, WR; Christensen, DB, 1998) |
| " Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25." | 2.68 | Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. ( Oliver, SD; Rapeport, WG; Wesnes, K; Williams, SA, 1996) |
| "The cause of Parkinsonism has been described as wide and elusive, however, environmental toxins and drugs accounts for large percentage of spontaneous cases in humans." | 1.42 | -NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism. ( Abdulbasit, A; Balogun, WG; Cobham, AE; Enye, LA; Ishola, AO; Nanakumo, ET; Obende, OM; Ogundele, OM, 2015) |
| "UHDRS (Unified Huntington's Disease Rating Scale) motor scores were obtained from medical records as an index of disease progression." | 1.42 | Examining Huntington's disease patient and informant concordance on frontally mediated behaviors. ( Cimino, CR; Hergert, DC; Sanchez-Ramos, J, 2015) |
| "Strategies to prevent and treat delirium during hospitalization for hip fracture have been less studied." | 1.40 | [Delirium prevention and treatment in elderly hip fracture]. ( Formiga, F; Robles, MJ; Vidán, MT, 2014) |
| "Here, we treated schizophrenia rat models with a systematic injection of MK-801 (0." | 1.40 | Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. ( Fang, Y; Xu, L; Zhang, C, 2014) |
| " Further study is needed to determine whether these results concerning mechanism and dosage can be the basis for prevention of the development of CIS in at risk populations." | 1.38 | Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. ( Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY, 2012) |
| "Treatment with haloperidol and clozapine attenuated the detrimental performance effects of these challenges, with clozapine exhibiting more robust attenuation." | 1.35 | Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. ( Martinez, V; Sarter, M, 2008) |
| "Schizophrenia is a neurodevelopmental disorder associated with persistent symptomatology, severe functional disability, and residual morbidity characteristic of neurodegenerative brain diseases." | 1.34 | Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. ( Jarskog, LF; Lieberman, JA; Perkins, DO, 2007) |
| "In haloperidol-induced catalepsy in rats (1." | 1.30 | Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. ( Cohen, S; Levy, R; Speiser, Z, 1998) |
| " The alleviation of the deficit with chronic administration of a DA precursor points to a possible line of treatment for the cognitive effects of developmental lead exposure." | 1.27 | Psychopharmacological investigations of a lead-induced long-term cognitive deficit in monkeys. ( Bowman, RE; Levin, ED; Vuchetich, J; Wegert, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (15.87) | 18.7374 |
| 1990's | 15 (11.90) | 18.2507 |
| 2000's | 70 (55.56) | 29.6817 |
| 2010's | 21 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campiani, G | 1 |
| Butini, S | 1 |
| Fattorusso, C | 1 |
| Catalanotti, B | 1 |
| Gemma, S | 1 |
| Nacci, V | 1 |
| Morelli, E | 1 |
| Cagnotto, A | 1 |
| Mereghetti, I | 1 |
| Mennini, T | 1 |
| Carli, M | 2 |
| Minetti, P | 1 |
| Di Cesare, MA | 1 |
| Mastroianni, D | 1 |
| Scafetta, N | 1 |
| Galletti, B | 1 |
| Stasi, MA | 1 |
| Castorina, M | 1 |
| Pacifici, L | 1 |
| Vertechy, M | 1 |
| Di Serio, S | 1 |
| Ghirardi, O | 1 |
| Tinti, O | 1 |
| Carminati, P | 1 |
| Herling, SF | 1 |
| Greve, IE | 1 |
| Vasilevskis, EE | 1 |
| Egerod, I | 1 |
| Bekker Mortensen, C | 1 |
| Møller, AM | 1 |
| Svenningsen, H | 1 |
| Thomsen, T | 1 |
| Robles, MJ | 1 |
| Formiga, F | 1 |
| Vidán, MT | 1 |
| Jones, C | 1 |
| Powell, A | 1 |
| Flynn, P | 1 |
| Rischbieth, S | 1 |
| McKellar, D | 1 |
| Mortimer, D | 1 |
| Gelfius, CD | 1 |
| Potts, MA | 1 |
| Zhang, C | 1 |
| Fang, Y | 1 |
| Xu, L | 1 |
| Phelps, TI | 1 |
| Bondi, CO | 1 |
| Ahmed, RH | 1 |
| Olugbade, YT | 1 |
| Kline, AE | 1 |
| Ogundele, OM | 1 |
| Nanakumo, ET | 1 |
| Ishola, AO | 1 |
| Obende, OM | 1 |
| Enye, LA | 1 |
| Balogun, WG | 1 |
| Cobham, AE | 1 |
| Abdulbasit, A | 1 |
| Pisani, MA | 1 |
| Araujo, KL | 1 |
| Murphy, TE | 1 |
| Hergert, DC | 1 |
| Sanchez-Ramos, J | 1 |
| Cimino, CR | 1 |
| Kat, MG | 1 |
| Vreeswijk, R | 2 |
| de Jonghe, JF | 2 |
| van der Ploeg, T | 1 |
| van Gool, WA | 2 |
| Eikelenboom, P | 2 |
| Kalisvaart, KJ | 2 |
| Kelley, ME | 1 |
| Haas, GL | 1 |
| van Kammen, DP | 2 |
| Bonham, C | 1 |
| Abbott, C | 1 |
| Barak, S | 1 |
| Weiner, I | 1 |
| Krakowski, MI | 1 |
| Czobor, P | 2 |
| Nolan, KA | 1 |
| Levine, SZ | 1 |
| Rabinowitz, J | 4 |
| Wölwer, W | 1 |
| Brinkmeyer, J | 1 |
| Riesbeck, M | 1 |
| Freimüller, L | 1 |
| Klimke, A | 2 |
| Wagner, M | 1 |
| Möller, HJ | 1 |
| Klingberg, S | 1 |
| Gaebel, W | 1 |
| Kelly, MP | 1 |
| Stein, JM | 1 |
| Vecsey, CG | 1 |
| Favilla, C | 1 |
| Yang, X | 1 |
| Bizily, SF | 1 |
| Esposito, MF | 1 |
| Wand, G | 1 |
| Kanes, SJ | 1 |
| Abel, T | 1 |
| González-Blanch, C | 1 |
| Crespo-Facorro, B | 3 |
| Alvarez-Jiménez, M | 1 |
| Rodríguez-Sánchez, JM | 2 |
| Pérez-Iglesias, R | 2 |
| Pelayo-Terán, JM | 1 |
| Martínez-García, O | 2 |
| Vázquez-Barquero, JL | 3 |
| Harvey, PD | 4 |
| Pappadopulos, E | 1 |
| Lombardo, I | 1 |
| Kremer, CM | 1 |
| Mata, I | 1 |
| Ayesa, R | 1 |
| Ramirez-Bonilla, M | 1 |
| Goldberg, TE | 1 |
| Gomar, JJ | 1 |
| Lipkovich, IA | 1 |
| Deberdt, W | 1 |
| Csernansky, JG | 2 |
| Sabbe, B | 1 |
| Keefe, RS | 5 |
| Kollack-Walker, S | 1 |
| Attupurath, R | 1 |
| Aziz, R | 1 |
| Wollman, D | 1 |
| Muralee, S | 1 |
| Tampi, RR | 1 |
| Calcagno, E | 1 |
| Mainolfi, P | 1 |
| Mainini, E | 1 |
| Invernizzi, RW | 1 |
| Krakowski, M | 1 |
| Babin, SL | 1 |
| Hood, AJ | 1 |
| Wassef, AA | 1 |
| Williams, NG | 1 |
| Patel, SS | 1 |
| Sereno, AB | 1 |
| Slor, CJ | 1 |
| Groot, E | 1 |
| Ploeg, TV | 1 |
| Snoeck, M | 1 |
| Schmand, B | 1 |
| Yeganeh-Doost, P | 1 |
| Gruber, O | 1 |
| Falkai, P | 3 |
| Schmitt, A | 2 |
| Galderisi, S | 1 |
| Mucci, A | 1 |
| Bitter, I | 2 |
| Libiger, J | 1 |
| Bucci, P | 1 |
| Fleischhacker, WW | 2 |
| Kahn, RS | 2 |
| Horiguchi, M | 1 |
| Hannaway, KE | 1 |
| Adelekun, AE | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 3 |
| Roiz-Santiáñez, R | 1 |
| Tordesillas-Gutiérrez, D | 1 |
| Ortíz-García de la Foz, V | 1 |
| Ayesa-Arriola, R | 1 |
| Gutiérrez, A | 1 |
| Tabarés-Seisdedos, R | 1 |
| Suzuki, H | 1 |
| Gen, K | 1 |
| Veselinovic, T | 1 |
| Schorn, H | 1 |
| Vernaleken, IB | 1 |
| Hiemke, C | 1 |
| Zernig, G | 1 |
| Gur, R | 1 |
| Gründer, G | 1 |
| Cohen, CI | 1 |
| Schoos, R | 1 |
| Artiola i Fortuny, L | 1 |
| Vester-Blockland, E | 1 |
| De Smedt, G | 1 |
| de Haan, L | 1 |
| van Amelsvoort, T | 1 |
| Aguglia, E | 1 |
| De Vanna, M | 1 |
| Onor, ML | 1 |
| Ferrara, D | 1 |
| Sumiyoshi, T | 1 |
| Abdul-Monim, Z | 1 |
| Reynolds, GP | 1 |
| Neill, JC | 1 |
| Ganguly, R | 1 |
| Miller, LS | 1 |
| Martin, BC | 1 |
| Brunnauer, A | 1 |
| Geiger, E | 1 |
| Laux, G | 2 |
| Wilson, MS | 1 |
| Gibson, CJ | 1 |
| Hamm, RJ | 1 |
| Heydebrand, G | 1 |
| Weiser, M | 1 |
| Hoff, AL | 2 |
| DeLisi, LE | 1 |
| Good, KP | 1 |
| Whitehorn, D | 1 |
| DeSmedt, G | 1 |
| Kopala, LC | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Seidman, LJ | 2 |
| Christensen, BK | 2 |
| Hamer, RM | 4 |
| Sharma, T | 4 |
| Sitskoorn, MM | 2 |
| Lewine, RR | 1 |
| Yurgelun-Todd, DA | 1 |
| Gur, RC | 1 |
| Tohen, M | 4 |
| Tollefson, GD | 4 |
| Sanger, TM | 2 |
| Lieberman, JA | 5 |
| Jones, CK | 1 |
| Eberle, EL | 1 |
| Shaw, DB | 1 |
| McKinzie, DL | 1 |
| Shannon, HE | 1 |
| Sawada, K | 1 |
| Barr, AM | 1 |
| Nakamura, M | 1 |
| Arima, K | 1 |
| Young, CE | 1 |
| Dwork, AJ | 1 |
| Phillips, AG | 1 |
| Honer, WG | 1 |
| Charles, C | 1 |
| Zipursky, R | 1 |
| Green, AI | 1 |
| Gur, RE | 1 |
| McEvoy, J | 1 |
| Perkins, D | 2 |
| Gu, H | 1 |
| Li, X | 1 |
| May, RS | 1 |
| Tolbert, LC | 1 |
| Jackson, WT | 1 |
| Flournoy, JM | 1 |
| Baxter, LR | 1 |
| Bertsch, T | 1 |
| Henning, U | 1 |
| Tost, H | 1 |
| Henn, FA | 1 |
| Garver, DL | 1 |
| Holcomb, JA | 1 |
| Christensen, JD | 1 |
| Hashimoto, K | 2 |
| Fujita, Y | 1 |
| Shimizu, E | 1 |
| Iyo, M | 1 |
| Rock, SL | 1 |
| Woolson, S | 1 |
| Rémillard, S | 1 |
| Pourcher, E | 1 |
| Cohen, H | 1 |
| Eerdekens, M | 1 |
| Davidson, M | 1 |
| Legris, P | 1 |
| McEvoy, JP | 1 |
| Johnson, J | 1 |
| Glick, ID | 1 |
| Dunn, MJ | 2 |
| Killcross, S | 2 |
| Woodward, ND | 1 |
| Purdon, SE | 3 |
| Zald, DH | 1 |
| Lee, BJ | 1 |
| Lee, JG | 1 |
| Kim, YH | 1 |
| Bespalov, A | 1 |
| Jongen-Rêlo, AL | 1 |
| van Gaalen, M | 1 |
| Harich, S | 1 |
| Schoemaker, H | 1 |
| Gross, G | 1 |
| Perkins, DO | 1 |
| Jarskog, LF | 1 |
| Morice, E | 1 |
| Billard, JM | 1 |
| Denis, C | 1 |
| Mathieu, F | 1 |
| Betancur, C | 1 |
| Epelbaum, J | 1 |
| Giros, B | 1 |
| Nosten-Bertrand, M | 1 |
| Limosin, F | 1 |
| Lindenmayer, JP | 1 |
| Khan, A | 1 |
| Iskander, A | 1 |
| Abad, MT | 1 |
| Parker, B | 1 |
| Didriksen, M | 1 |
| Skarsfeldt, T | 1 |
| Arnt, J | 1 |
| Amitai, N | 1 |
| Semenova, S | 1 |
| Markou, A | 1 |
| Buchsbaum, MS | 1 |
| Haznedar, MM | 1 |
| Aronowitz, J | 1 |
| Brickman, AM | 1 |
| Newmark, RE | 1 |
| Bloom, R | 1 |
| Brand, J | 1 |
| Goldstein, KE | 1 |
| Heath, D | 1 |
| Starson, M | 1 |
| Hazlett, EA | 1 |
| Mihara, T | 1 |
| Mihara, K | 1 |
| Yarimizu, J | 1 |
| Mitani, Y | 1 |
| Matsuda, R | 1 |
| Yamamoto, H | 1 |
| Aoki, S | 1 |
| Akahane, A | 1 |
| Iwashita, A | 1 |
| Matsuoka, N | 1 |
| Perlick, DA | 1 |
| Rosenheck, RA | 1 |
| Kaczynski, R | 1 |
| Bingham, S | 1 |
| Collins, J | 1 |
| Karasawa, J | 1 |
| Chaki, S | 1 |
| Kim, JH | 1 |
| Byun, HJ | 1 |
| Sergi, MJ | 1 |
| Green, MF | 1 |
| Widmark, C | 1 |
| Reist, C | 1 |
| Erhart, S | 1 |
| Braff, DL | 1 |
| Kee, KS | 1 |
| Marder, SR | 1 |
| Mintz, J | 1 |
| Terry, AV | 1 |
| Gearhart, DA | 1 |
| Warner, S | 1 |
| Hohnadel, EJ | 1 |
| Middlemore, ML | 1 |
| Zhang, G | 1 |
| Bartlett, MG | 1 |
| Mahadik, SP | 1 |
| Egashira, N | 1 |
| Ishigami, N | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Gallhofer, B | 1 |
| Jaanson, P | 1 |
| Mittoux, A | 1 |
| Tanghøj, P | 1 |
| Lis, S | 1 |
| Krieger, S | 1 |
| Martinez, V | 1 |
| Sarter, M | 1 |
| Goetghebeur, P | 1 |
| Dias, R | 1 |
| Caroff, SN | 1 |
| Conn, LM | 1 |
| Lion, JR | 1 |
| Lampke, RS | 1 |
| Busch, KT | 1 |
| Schulz, H | 1 |
| Bergman, A | 1 |
| O'Brien, J | 1 |
| Osgood, G | 1 |
| Cornblatt, B | 1 |
| Gilbertson, MW | 1 |
| Yao, JK | 1 |
| Williams, SA | 1 |
| Wesnes, K | 1 |
| Oliver, SD | 1 |
| Rapeport, WG | 1 |
| Strite, D | 1 |
| Valentine, AD | 1 |
| Meyers, CA | 1 |
| Stanislav, SW | 1 |
| Addington, J | 1 |
| Addington, D | 2 |
| Arnsten, AF | 1 |
| Goldman-Rakic, PS | 1 |
| Speiser, Z | 1 |
| Levy, R | 1 |
| Cohen, S | 1 |
| Christensen, DB | 1 |
| Benfield, WR | 1 |
| Jentsch, JD | 1 |
| Taylor, JR | 1 |
| Redmond, DE | 1 |
| Elsworth, JD | 1 |
| Youngren, KD | 1 |
| Roth, RH | 1 |
| Breier, A | 2 |
| Velligan, DI | 2 |
| Miller, AL | 2 |
| Gracey, DJ | 1 |
| Bell, R | 1 |
| King, DJ | 1 |
| Jones, BD | 1 |
| Stip, E | 1 |
| Labelle, A | 2 |
| David, SR | 1 |
| Allain, H | 1 |
| Dautzenberg, PH | 1 |
| Maurer, K | 1 |
| Schuck, S | 1 |
| Bonhomme, D | 1 |
| Gérard, D | 1 |
| Bhana, N | 1 |
| Foster, RH | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Malla, A | 1 |
| Lit, W | 1 |
| Feifel, D | 1 |
| Priebe, K | 1 |
| Potkin, SG | 1 |
| Fleming, K | 1 |
| Jin, Y | 1 |
| Gulasekaram, B | 1 |
| Newcomer, J | 1 |
| Pultz, J | 1 |
| Csernansky, J | 1 |
| Mahurin, R | 1 |
| Weiss, E | 1 |
| Kemmler, G | 1 |
| Scharbach, H | 1 |
| Caine, ED | 1 |
| Margolin, DI | 1 |
| Brown, GL | 1 |
| Ebert, MH | 1 |
| Kay, SR | 1 |
| Singh, MM | 2 |
| Cookson, IB | 1 |
| Owen, F | 1 |
| Ridges, AP | 1 |
| Strauss, WH | 2 |
| Klieser, E | 2 |
| Austin, LS | 1 |
| Arana, GW | 1 |
| Melvin, JA | 1 |
| Berger, HJ | 1 |
| van Hoof, JJ | 1 |
| van Spaendonck, KP | 1 |
| Horstink, MW | 1 |
| van den Bercken, JH | 1 |
| Jaspers, R | 1 |
| Cools, AR | 1 |
| Classen, W | 1 |
| Luethcke, H | 1 |
| Levin, ED | 1 |
| Bowman, RE | 1 |
| Wegert, S | 1 |
| Vuchetich, J | 1 |
| van der Mast, RC | 1 |
| Moleman, P | 1 |
| Cohen-Mansfield, J | 1 |
| Franzén, G | 1 |
| Angrist, B | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Gershon, S | 1 |
| Logue, PE | 1 |
| Platzek, D | 1 |
| Hutzell, R | 1 |
| Robinson, B | 1 |
| Vallecorsi, G | 1 |
| Bavazzano, A | 1 |
| Zolotnitskii, RI | 1 |
| Kutsenok, BM | 1 |
| Gastev, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Regional Anaesthesia and General Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Hip Fracture Surgery: a Multicenter Randomized Controlled Trial.[NCT02213380] | 950 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Clozapine and Olanzapine in the Treatment of Violence in Schizophrenic Patients[NCT01123408] | 110 participants (Actual) | Interventional | 1999-06-30 | Completed | |||
| Effectiveness of the RemedRugby Program, a Program of Ecological Cognitive Remediation of Social Cognition Disorders in Schizophrenia[NCT03775564] | 60 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia[NCT00007774] | Phase 4 | 600 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| The Cognitive Effects of Risperidone and Olanzapine[NCT00108368] | Phase 4 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Differences by Sex and Genotype in the Effects of Stress on Executive Functions[NCT04273880] | Phase 1 | 146 participants (Anticipated) | Interventional | 2018-04-28 | Recruiting | ||
| Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates[NCT00865332] | 0 participants (Actual) | Observational | 2007-12-12 | Withdrawn | |||
| Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia? A Randomized Controlled Trial.[NCT04347668] | 266 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | |||
| Low Dose Ionizing Radiation Using CT Scans as a Potential Therapy for Alzheimer's Dementia (LDIR-CT-AD) Trial: A Pilot Study[NCT03597360] | 4 participants (Actual) | Interventional | 2019-01-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mortality within 30 days post operation (NCT02213380)
Timeframe: 30 days after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Group RA | 8 |
| Group GA | 4 |
The worst pain score within 7 days post-operation in both groups. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain(0 point) to worst pain (100 points). (NCT02213380)
Timeframe: In 7days post operation
| Intervention | score on a scale (Median) |
|---|---|
| Group RA | 0 |
| Group GA | 0 |
Costs of anesthetic procedure only (NCT02213380)
Timeframe: 1 day after operation
| Intervention | dollars (Median) |
|---|---|
| Group RA | 159 |
| Group GA | 268 |
Length of hospital stay are measured from the anesthesia starting day to the discharge day (NCT02213380)
Timeframe: till the day of discharge from hospital, an average of 7 days
| Intervention | days (Median) |
|---|---|
| Group RA | 7 |
| Group GA | 7 |
Post-operative delirium diagnosed with Confusion Assessment Method (NCT02213380)
Timeframe: in 7 days post operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Group RA | 29 |
| Group GA | 24 |
The worst severity scores of delirium was diagnosed with the DRS-R-98 within 7 days (NCT02213380)
Timeframe: within first 7days post operation
| Intervention | score on a scale (Mean) |
|---|---|
| Group RA | 23.48 |
| Group GA | 24.22 |
Entire expenditure in-hospital (NCT02213380)
Timeframe: till the day of discharge
| Intervention | dollars (Median) |
|---|---|
| Group RA | 5582 |
| Group GA | 5908 |
9 reviews available for haloperidol and Cognition Disorders
| Article | Year |
|---|---|
Interventions for preventing intensive care unit delirium in adults.
Topics: Aged; Antipsychotic Agents; Cognition Disorders; Cognitive Behavioral Therapy; Delirium; Female; Hal | 2018 |
Are second generation antipsychotics a distinct class?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Haloperidol; Humans; Q | 2008 |
The role of the cerebellum in schizophrenia: from cognition to molecular pathways.
Topics: Animals; Antipsychotic Agents; Cerebellum; Cognition Disorders; Glutamic Acid; Haloperidol; Humans; | 2011 |
A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects.
Topics: Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Ha | 2007 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
Pharmacologic approaches to violence.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Be | 1984 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; H | 1999 |
Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Dibenzothiazepines; Haloperidol; Humans; Male; Mod | 1999 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
41 trials available for haloperidol and Cognition Disorders
| Article | Year |
|---|---|
Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Arthroplasty, Replacement, Hip; Case-Control Studies; | 2008 |
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Double-Bli | 2008 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis | 2010 |
Neuropsychological impairments predict the clinical course in schizophrenia.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Cognition Disorders; Double-Blind Method; Female; | 2008 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male | 2008 |
Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Cognition Disorders; Double-Blind Method; Fema | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe | 2009 |
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow-Up Studies; Halope | 2009 |
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body | 2011 |
Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study.
Topics: Adult; Antipsychotic Agents; Cognition; Cognition Disorders; Female; Haloperidol; Humans; Inpatients | 2011 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzot | 2013 |
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cerebral Corte | 2012 |
The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Diagnosis, Comp | 2012 |
Effects of antipsychotic treatment on cognition in healthy subjects.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Aripiprazole; Attention; Brain; Cognition | 2013 |
Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study.
Topics: Adult; Antipsychotic Agents; Australia; Austria; Canada; Clinical Trials as Topic; Cognition Disorde | 2003 |
Correlates of cognitive deficits in first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Diagnostic and Statistical Manual of M | 2004 |
The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Double-Blind Method; Factor Analy | 2004 |
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Antipsychotic drug effects on brain morphology in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Caudate Nucleus; Cognition Disorders; Female; H | 2005 |
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Drug Ther | 2005 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studie | 2005 |
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; | 2006 |
The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
Topics: Adult; Antipsychotic Agents; Brain; Cognition; Cognition Disorders; Double-Blind Method; Female; Fol | 2005 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administra | 2005 |
Insight in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Brain; Cognition Disor | 2006 |
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Chronic Disease; Cognition Disorders; Donepe | 2007 |
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; Cognition Disorders; Com | 2007 |
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Topics: Activities of Daily Living; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cogn | 2008 |
Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Discrimination, Psychological; Double- | 2007 |
Memory and plasma HVA changes in schizophrenia: are they episode markers?
Topics: Adult; Biomarkers; Cognition Disorders; Double-Blind Method; Haloperidol; Homovanillic Acid; Humans; | 1994 |
Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.
Topics: 1-Naphthylamine; Adolescent; Adult; Cognition; Cognition Disorders; Dose-Response Relationship, Drug | 1996 |
Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Haloperidol; Humans; Neuropsychologi | 1997 |
Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients.
Topics: Aged; Aged, 80 and over; Alprazolam; Anti-Anxiety Agents; Antipsychotic Agents; Behavioral Symptoms; | 1998 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Me | 2000 |
Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment.
Topics: Aged; Aged, 80 and over; Aggression; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; | 2000 |
Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Decision Making; Dibenzothiazepines; Double-Blind | 2001 |
Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Clozapine; Cognition; Cognition Disorders; Cross- | 2001 |
Does cognitive function improve with quetiapine in comparison to haloperidol?
Topics: Antipsychotic Agents; Cognition Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Ne | 2002 |
Cognitive disturbances in neuroleptic therapy.
Topics: Adult; Antipsychotic Agents; Benzamides; Cognition Disorders; Double-Blind Method; Haloperidol; Huma | 1990 |
Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Flupenthixol; Haloperidol; Humans; Male; P | 1988 |
Psychopharmacological study of schizophrenia--some ways out of an impasse. A case study with haloperidol.
Topics: Acute Disease; Benztropine; Clinical Trials as Topic; Cognition Disorders; Dose-Response Relationshi | 1973 |
76 other studies available for haloperidol and Cognition Disorders
| Article | Year |
|---|---|
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzothiepins; Catalepsy; Cognition Disorders; Do | 2004 |
[Delirium prevention and treatment in elderly hip fracture].
Topics: Aged; Anesthesia, Epidural; Anesthesia, General; Benzodiazepines; Cognition Disorders; Combined Moda | 2014 |
What's new on the post-ICU burden for patients and relatives?
Topics: Antipsychotic Agents; Cognition Disorders; Critical Illness; Delirium; Family; Haloperidol; Humans; | 2013 |
Managing severe aggression in frontotemporal dementia.
Topics: Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Death; Fatal Outcome; | 2014 |
Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report.
Topics: Adolescent; Amantadine; Carbidopa; Cerebral Palsy; Cognition Disorders; Dopamine Agonists; Dopamine | 2013 |
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders; Disease Model | 2014 |
Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; Bromocriptine; Cognition Disorders; | 2015 |
-NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Calcium; Cognition Disorders; Disease Models, Animal; Disease | 2015 |
Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients.
Topics: Age Factors; Aged; Aged, 80 and over; APACHE; Cognition Disorders; Delirium; Dose-Response Relations | 2015 |
Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
Topics: Adult; Aged; Antipsychotic Agents; Awareness; Cognition Disorders; Disease Progression; Female; Fron | 2015 |
Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.
Topics: Adult; Age of Onset; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Cohort Studies; Dis | 2008 |
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Attention; Cholinergic Antagonists; Clozapine; Cognition Disorders; C | 2009 |
Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
Topics: Acetylcysteine; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; Animals, Newborn; | 2009 |
Targeting cognition in schizophrenia research: from etiology to treatment.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dibenzothiazepin | 2009 |
Chorea associated with gabapentin use in an elderly man.
Topics: Aged; Amines; Analgesics; Anti-Dyskinesia Agents; Anxiety; Chorea; Cognition Disorders; Cyclohexanec | 2009 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines | 2011 |
Anesthesia and postoperative delirium in older adults undergoing hip surgery.
Topics: Aged; Anesthesia, Conduction; Anesthesia, General; Cognition Disorders; Delirium; Female; Haloperido | 2011 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Halo | 2012 |
Schizophrenia. Management issues that complicate care of older persons.
Topics: Age Factors; Aged; Antipsychotic Agents; Cognition Disorders; Comorbidity; Haloperidol; Health Servi | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenze | 2002 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Hal | 2002 |
Atypical antipsychotic drugs improve cognition in schizophrenia.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Follow-Up Studies; Haloperidol; Huma | 2003 |
The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Excitatory Amino Acid Antagoni | 2003 |
Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cost-Benefit Analysis; Drug Administration Schedul | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combinat | 2003 |
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Cognition Diso | 2003 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats.
Topics: Acoustic Stimulation; Animals; Apomorphine; Benzazepines; Cognition Disorders; Dose-Response Relatio | 2005 |
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
Topics: Adaptor Proteins, Vesicular Transport; Aged; Animals; Antipsychotic Agents; Behavior, Animal; Cognit | 2005 |
Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Clozapine; Cognition Disorders; Depressive Disorder, Ma | 2005 |
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition Disorder | 2005 |
[Paranoid delirium of cognition].
Topics: Antipsychotic Agents; Child; Cognition Disorders; Delirium; Haloperidol; Humans; Middle Aged; Parano | 2005 |
Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Clozapine; Cognition Disorders; Conditioning, O | 2006 |
Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs.
Topics: Amino Acids; Animals; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; E | 2007 |
Clozapine, SCH 23390 and alpha-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Clozapine; Cogn | 2007 |
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Benzodiazepines; Cerebral Cortex; Child; Cognition | 2007 |
Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia.
Topics: Animals; Brain Diseases, Metabolic; Cognition Disorders; Disease Models, Animal; Dopamine; Dopamine | 2007 |
Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition Disorder | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzoth | 2007 |
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Female; Fluoro | 2007 |
Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Aminopyridines; Ani | 2007 |
D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Clozapine; Cognition; Cognition Disorders; Dizo | 2008 |
Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Fem | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Fa | 2007 |
Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.
Topics: Acetylcholine; Administration, Oral; Animals; Antipsychotic Agents; Basal Nucleus of Meynert; Brain; | 2007 |
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders | 2008 |
Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia.
Topics: Animals; Attention; Clozapine; Cognition; Cognition Disorders; Disease Models, Animal; Haloperidol; | 2008 |
Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.
Topics: Animals; Antipsychotic Agents; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; C | 2009 |
The neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Autonomic Nervous System; Cognition Disorders; Consciousness Disorders; Diagno | 1980 |
Interviewing with intravenous drugs.
Topics: Amobarbital; Cognition Disorders; Confusion; Diagnosis, Differential; Haloperidol; Humans; Infusions | 1982 |
[The acute psychiatric emergency].
Topics: Acute Disease; Aged; Alcoholism; Amitriptyline; Brain Ischemia; Cognition Disorders; Consciousness D | 1981 |
Distractibility in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Attention; Chronic Disease; Cognition Disord | 1995 |
Manic episodes in two patients treated with interferon alpha.
Topics: Adult; Bipolar Disorder; Clonazepam; Cognition Disorders; Dopamine Antagonists; Female; GABA Modulat | 1997 |
Cognitive effects of antipsychotic agents in persons with traumatic brain injury.
Topics: Adult; Antipsychotic Agents; Brain Damage, Chronic; Brain Injuries; Cognition Disorders; Haloperidol | 1997 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
Topics: Aging; alpha-Methyltyrosine; Animals; Avoidance Learning; Catalepsy; Cognition; Cognition Disorders; | 1998 |
Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys.
Topics: Animals; Chlorocebus aethiops; Cognition Disorders; Dopamine; Dopamine Antagonists; Dopamine D2 Rece | 1999 |
[Neuro-cognition and schizophrenia. 11th World Congress for Psychiatry. Hamburg, 8 August 1999].
Topics: Antipsychotic Agents; Cognition Disorders; Haloperidol; Humans; Risperidone; Schizophrenia | 1999 |
PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Haloperidol; Indoles; Male; Meglumine; Rats; Rat | 2000 |
Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Drug Administration Schedule; Gait Disorders, Ne | 2001 |
Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
Topics: Antipsychotic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Adminis | 2002 |
[Mental complications of neuroleptic drugs. Confusional oneiric states].
Topics: Antipsychotic Agents; Cognition Disorders; Confusion; Female; Haloperidol; Humans; Mental Disorders; | 1978 |
Gilles de la Tourette's syndrome, tardive dyskinesia, and psychosis in an adolescent.
Topics: Adolescent; Cognition Disorders; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloper | 1978 |
Cognitive abnormality in schizophrenia: a dual-process model.
Topics: Adolescent; Adult; Arousal; Attention; Chlorpromazine; Cognition Disorders; Color Perception; Concep | 1979 |
Platelet monoamine oxidase activity during the course of a schizophreniform psychosis.
Topics: Blood Platelets; Cognition Disorders; Delusions; Emotions; Hallucinations; Haloperidol; Humans; Male | 1975 |
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients.
Topics: Aged; Antidepressive Agents; Cognition Disorders; Depressive Disorder; Drug Interactions; Drug Thera | 1990 |
Haloperidol and cognitive shifting.
Topics: Attention; Basal Ganglia; Cognition Disorders; Female; Frontal Lobe; Haloperidol; Humans; Male; Midd | 1989 |
Dyscognitive syndromes in neuroleptic therapy.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Haloperidol; Humans; Male; Psychiatric Sta | 1988 |
Psychopharmacological investigations of a lead-induced long-term cognitive deficit in monkeys.
Topics: Acetylcholine; Amphetamine; Animals; Behavior, Animal; Cognition Disorders; Dopamine; Haloperidol; L | 1987 |
[Delirium in the general hospital].
Topics: Aged; Benzodiazepines; Cognition Disorders; Delirium; Haloperidol; Humans; Middle Aged; Prognosis; R | 1988 |
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated.
Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H | 1986 |
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated.
Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H | 1986 |
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated.
Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H | 1986 |
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated.
Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H | 1986 |
Serum cortisol in chronic schizophrenia. A study of the adrenocortical response to intravenously administered insulin and ACTH.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Age Factors; Aged; Amitriptyline; Blood Glucose; Chlorp | 1971 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Neurological, neuropsychological and behavioral aspects of Gilles de la Tourette's syndrome: a case.
Topics: Adolescent; Brain Damage, Chronic; Child; Cognition Disorders; Electroencephalography; Haloperidol; | 1973 |
[Haloperidol in the treatment of mental confusion in the aged].
Topics: Aged; Cognition Disorders; Dementia; Female; Haloperidol; Humans; Male; Psychomotor Disorders | 1971 |
[On the results of treatment and complications during the use of haloperidol in patients with long-term schizophrenia].
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Catatonia; Chlorpromazine; Cognition Disorders; Hall | 1969 |